| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisals TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer and TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
|
Medicine details |
|
| Medicine name | palbociclib (Ibrance®) |
| Formulation | 75 mg, 100 mg, 125 mg capsule |
| Reference number | 2392 |
| Indication | Treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer: in combination with an aromatase inhibitor; in combination with fulvestrant in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone agonist |
| Company | Pfizer Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 03/02/2017 |
| NICE guidance | |
| Commercial arrangement | PAS |